Inflammation in coronary artery disease: potential role for immunomodulatory therapy.
Understanding of the mechanisms underlying atherosclerotic disorders has evolved beyond the view of a progressive collection of lipids and cellular debris in the vascular wall. Current evidence has implicated inflammatory pathways as an important pathogenic mechanism in atherogenesis and plaque destabilization. Although not necessarily the primary event, inflammation and cytokine activation during plaque formation and destabilization may represent a common final pathway to various stimuli. Thus, it seems that not only 'new' risk factors, such as infections with various microorganisms, but also classic risk factors for cardiovascular disease, such as hyperlipidemia, hypertension and diabetes, may promote their atherogenic effects through inflammatory responses. Indeed, recent reports have suggested that traditional cardiovascular medications may attenuate atherogenesis and enhance plaque stability, at least partly through anti-inflammatory mechanisms. However, uncovering the inflammatory pathways in atherosclerosis has raised the possibility that newer treatment modalities should be more directly targeted against inflammatory mediators. Recently, a series of experimental studies have reported reduction of atherosclerosis by immunomodulatory therapy, such as chemokine blockade, interleukin-10 and immunization/vaccination against oxidized low-density lipoprotein and heat-shock protein. It is conceivable that some of these approaches will be tested clinically and, if successful, they could provide novel treatment strategies in coronary artery disease in humans.
Aukrust
Pål
P
Research Institute for Internal Medicine, Medical Department, Rikshospitalet University Hospital, Sognsvannsveien 20, 0027 Oslo, Norway. pal.aukrust@rikshospitalet.no
Yndestad
Arne
A
Waehre
Torgun
T
Gullestad
Lars
L
Halvorsen
Bente
B
Damås
Jan Kristian
JK
D000818:Animals; D003324:Coronary Artery Disease / Q000188:drug therapy* / Q000209:etiology*; D006801:Humans; D007155:Immunologic Factors / Q000627:therapeutic use*; D007249:Inflammation / Q000150:complications*
D007155:Immunologic Factors